Stopping adalimumab associated with high rates of low disease activity in RA
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
3 y after discontinuing adalimumab (ADA), 4 in 5 patients with rheumatoid arthritis (RA) in this observational study remained in low disease activity (LDA), with fewer adverse events than those who continued ADA.
Continuing ADA led to higher rates of LDA as well as of adverse events.
Why this matters
Although effective in RA, biological agents like ADA are associated with higher infection risk.
The long-term safety and efficacy of continuing vs discontinuing ADA have been unclear.
At wk 208, 95.1% of ADA continuation patients and 79.7% of ADA discontinuation patients had LDA.
The ADA discontinuation group had significantly fewer adverse events vs continuation group (9.7% vs 32.9%; P<.001).
HOPEFUL-3 was 2-y observational study of 135 participants of HOPEFUL-2 and -1.